文献速递前列腺增生与排尿功能障碍

米拉贝隆50mg与抗胆碱能单药或联合治疗膀胱过度活动症的系统评价与网络Meta分析

Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
PubMed 文献 · Eur Urol · 2018-04-23

结果显示米拉贝隆50mg疗效显著优于安慰剂,与多数抗胆碱能药物相当,但口干、便秘和尿潴留等不良事件显著更少;索利那新5mg联合米拉贝隆25或50mg对部分或全部结局疗效更优,但伴有抗胆碱能副作用。

要点

  • 米拉贝隆50mg疗效显著优于安慰剂,与多数抗胆碱能药物相当。
  • 米拉贝隆50mg口干、便秘和尿潴留发生率显著低于多数活性对照药。
  • 索利那新5mg联合米拉贝隆25或50mg对部分或全部结局疗效更优,但抗胆碱能副作用更多。

核心结论

  • 米拉贝隆50mg对OAB关键症状的缓解显著优于安慰剂,与多种常用抗胆碱能药物相似,且口干等抗胆碱能副作用显著更少。
  • 索利那新5mg联合米拉贝隆25或50mg相比米拉贝隆50mg单药似乎提供疗效获益,但伴有各自抗胆碱能药物的预期副作用。

研究设计与样本

  • 系统文献综述与随机对照试验的网络Meta分析,检索2000—2017年评估OAB合格治疗的随机对照试验。

主要发现

  • 米拉贝隆50mg在所有疗效终点上均显著优于安慰剂。
  • 米拉贝隆50mg与多数活性治疗总体疗效相当,但索利那新10mg单药及索利那新5mg联合米拉贝隆25或50mg对部分或全部结局更有效。
  • 米拉贝隆50mg在口干、便秘和尿潴留方面分别显著优于21/22、9/20和7/10个活性对照药;其余终点上米拉贝隆50mg与所有治疗(包括安慰剂)总体耐受性相似。

关键数值与推荐

  • 疗效评估包括排尿频率、急迫性尿失禁、干爽率和尿失禁减少50%。
  • 耐受性评估包括口干、便秘、视力模糊和高血压。
  • 米拉贝隆50mg在口干方面显著优于21/22个活性对照药,便秘优于9/20,尿潴留优于7/10。

临床怎么用

  • 米拉贝隆50mg可作为OAB患者替代抗胆碱能治疗的选择,尤其适用于关注口干、便秘或尿潴留风险者。
  • 对部分症状控制不佳者,可考虑索利那新5mg联合米拉贝隆25或50mg,但需权衡抗胆碱能副作用增加。

局限性

  • 研究局限性包括不同试验间某些终点定义存在差异。
  • 可用数据存在异质性,例如不同终点评估的对照治疗研究数量和患者数不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mirabegron is an established treatment alternative to antimuscarinic therapy for patients with overactive bladder (OAB), as shown by efficacy and tolerability data from phase III trials. OBJECTIVE: To assess efficacy and tolerability of mirabegron 50mg versus antimuscarinic monotherapies and combination therapies. DESIGN, SETTING, AND PARTICIPANTS: Systematic literature review and network meta-analysis of randomised controlled trials (2000-2017) assessing eligible treatments for OAB. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Efficacy assessments included micturition frequency, urgency urinary incontinence, dry rate, and 50% reduction in incontinence. Tolerability assessments included dry mouth, constipation, blurred vision, and hypertension. RESULTS AND LIMITATIONS: A total of 64 studies (n=46 666) were included in the network meta-analysis. Mirabegron 50mg was significantly more efficacious than placebo for all efficacy endpoints. Comparable overall efficacy was observed for mirabegron 50mg versus most active treatments, but solifenacin 10mg monotherapy and solifenacin 5mg plus mirabegron 25 or 50mg in combination were more efficacious for some/all outcomes. Mirabegron 50mg was significantly better tolerated regarding dry mouth, constipation, and urinary retention than 21/22, 9/20, and 7/10 active comparators, respectively; similar overall tolerability was observed between mirabegron 50mg and all treatments (including placebo) for the remaining endpoints. Limitations of the study included between-trial variations in the definition of certain endpoints and heterogeneity of the available data (eg, number of studies and patients assessed) for comparator treatments across different endpoints. CONCLUSIONS: The relief of key OAB symptoms produced by mirabegron 50mg is significantly better than placebo, and similar to a range of common antimuscarinics, with the benefit of significantly fewer bothersome anticholinergic side effects such as dry mouth. Combination treatment of solifenacin 5mg plus mirabegron 25 or 50mg appears to provide an efficacy benefit compared with mirabegron 50mg, with the expected side effects of individual antimuscarinics. PATIENT SUMMARY: This study assessed the efficacy and tolerability of different drug treatments for OAB. Mirabegron 50mg was as effective as antimuscarinic therapy, with fewer common, bothersome side effects such as dry mouth, constipation, and urinary retention. Combination treatment of solifenacin 5mg plus mirabegron 25 or 50mg was more effective than mirabegron 50mg alone, but with more anticholinergic side effects.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Kelleher C, Hakimi Z, Zur R, et al. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. Eur Urol. 2018. PMID: 29699858. doi:10.1016/j.eururo.2018.03.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。